Callitas Health Inc (CSE:LILY) (OTCQB:MPHMF) announced Thursday that it has signed a letter of intent with NuEthix LLC to manufacture and supply its own CannaStrip products for retail sale in the US via the nutrition and fitness channel.
The new partnership comes on the heels of the clinical-stage pharmaceutical company signing agreements with two undisclosed California companies to market and sell CannStrips for THC and cannabidiols (CBD), a medical component of cannabis that doesn’t get users high.
READ: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs
In a statement, James Thompson, Callitas CEO said the move represented his company’s latest advance into the cannabinoid market.
“Our agreement with NuEthix for CannaStrips in the nutrition and fitness segment is just one more step toward making Callitas a stronger player in the rapidly-expanding cannabinoid market,” Thompson said.
“We’re looking forward to this mutually-beneficial partnership and working with NuEthix to develop advanced, proprietary formulations of the CannaStrip technology for their customers.”
NuEthix Formulations is a nutritional supplement company based in Cincinnati, Ohio.
Formed in early 2015, Callitas Health is developing innovative remedies for weight management, female sexual health, cannabis delivery technologies and other proprietary drugs.
Contact Ellen Kelleher at [email protected]